EP3930747A4 - Immuntherapeutische kombination zur behandlung von krebs - Google Patents
Immuntherapeutische kombination zur behandlung von krebs Download PDFInfo
- Publication number
- EP3930747A4 EP3930747A4 EP20763489.0A EP20763489A EP3930747A4 EP 3930747 A4 EP3930747 A4 EP 3930747A4 EP 20763489 A EP20763489 A EP 20763489A EP 3930747 A4 EP3930747 A4 EP 3930747A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treating cancer
- immunotherapeutic combination
- immunotherapeutic
- combination
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962811459P | 2019-02-27 | 2019-02-27 | |
US201962825487P | 2019-03-28 | 2019-03-28 | |
US201962838180P | 2019-04-24 | 2019-04-24 | |
US201962881832P | 2019-08-01 | 2019-08-01 | |
PCT/US2020/020224 WO2020176797A1 (en) | 2019-02-27 | 2020-02-27 | Immunotherapeutic combination for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3930747A1 EP3930747A1 (de) | 2022-01-05 |
EP3930747A4 true EP3930747A4 (de) | 2023-04-05 |
Family
ID=72238533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20763489.0A Withdrawn EP3930747A4 (de) | 2019-02-27 | 2020-02-27 | Immuntherapeutische kombination zur behandlung von krebs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3930747A4 (de) |
JP (1) | JP2022521792A (de) |
CN (1) | CN113631185A (de) |
WO (1) | WO2020176797A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230165952A1 (en) | 2020-05-01 | 2023-06-01 | Nykode Therapeutics ASA | Betacoronavirus prophylaxis and therapy |
BR112023019610A2 (pt) | 2021-03-26 | 2023-12-12 | Genentech Inc | Método para tratar um sujeito com câncer, e, kit |
WO2022233851A1 (en) | 2021-05-03 | 2022-11-10 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
EP4337248A2 (de) | 2021-05-10 | 2024-03-20 | Nykode Therapeutics ASA | Koexpression von konstrukten und immunstimulatorischen verbindungen |
KR20240019136A (ko) | 2021-05-10 | 2024-02-14 | 니코데 테라퓨틱스 에이에스에이 | 작제물과 면역억제 화합물의 공동발현 |
WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
JP2024516893A (ja) | 2021-05-10 | 2024-04-17 | ナイコード セラピューティクス アルメン アクスイェ セルスカプ | 寛容誘導構築物及び組成物並びに免疫障害の処置のためのそれらの使用 |
AU2022275002A1 (en) | 2021-05-10 | 2023-11-09 | Nykode Therapeutics ASA | Tolerance-inducing constructs and composition and their use for the treatment of immune disorders |
AU2022381515A1 (en) | 2021-11-03 | 2024-05-09 | Adaptive Biotechnologies Corporation | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170216403A1 (en) * | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
WO2018089669A2 (en) * | 2016-11-10 | 2018-05-17 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA43362A (fr) * | 2015-05-26 | 2018-10-10 | Advaxis Inc | Immunothérapie à base de vecteurs d'administration personnalisés, et leurs utilisations |
BR112018013881A8 (pt) * | 2016-01-08 | 2023-05-09 | Vaccibody As | Vacina de neoepítopo anticâncer terapêutica |
US20190307868A1 (en) * | 2016-03-31 | 2019-10-10 | Neon Therapeutics, Inc. | Neoantigens and methods of their use |
CA3034771C (en) * | 2016-08-25 | 2021-10-26 | Nantomics, Llc | Immunotherapy markers and uses therefor |
EP3641803A2 (de) * | 2017-06-21 | 2020-04-29 | Transgene | Personalisierter impfstoff |
-
2020
- 2020-02-27 CN CN202080025990.8A patent/CN113631185A/zh active Pending
- 2020-02-27 JP JP2021550014A patent/JP2022521792A/ja active Pending
- 2020-02-27 EP EP20763489.0A patent/EP3930747A4/de not_active Withdrawn
- 2020-02-27 WO PCT/US2020/020224 patent/WO2020176797A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170216403A1 (en) * | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
WO2018089669A2 (en) * | 2016-11-10 | 2018-05-17 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
Non-Patent Citations (3)
Title |
---|
ELIZABETH I. BUCHBINDER ET AL: "CTLA-4 and PD-1 Pathways : Similarities, Differences, and Implications of Their Inhibition", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS)., vol. 39, no. 1, 1 February 2016 (2016-02-01), US, pages 98 - 106, XP055393184, ISSN: 0277-3732, DOI: 10.1097/COC.0000000000000239 * |
See also references of WO2020176797A1 * |
XUE WEI ET AL: "SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors", ONCOTARGET, vol. 7, no. 50, 13 December 2016 (2016-12-13), pages 83088 - 83100, XP093025668, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347755/pdf/oncotarget-07-83088.pdf> DOI: 10.18632/oncotarget.13070 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020176797A1 (en) | 2020-09-03 |
JP2022521792A (ja) | 2022-04-12 |
EP3930747A1 (de) | 2022-01-05 |
CN113631185A (zh) | 2021-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3930747A4 (de) | Immuntherapeutische kombination zur behandlung von krebs | |
EP3781564A4 (de) | Verbindungen zur behandlung von krebs | |
EP3892282A4 (de) | Kombinationen zur behandlung von krebs | |
EP3706770A4 (de) | Immuntherapeutische kombination zur behandlung von krebs | |
EP3836909A4 (de) | Biomarker für die krebstherapie | |
GB201903546D0 (en) | Cancer treatment | |
IL285807A (en) | Immunotherapy for cancer treatment | |
IL287907A (en) | Cancer treatment methods | |
EP3820461A4 (de) | Verfahren zur behandlung von krebs | |
EP3755711A4 (de) | Immuntherapeutische zusammensetzung zur behandlung von krebs | |
EP3946456A4 (de) | Zielgerichtete synergistische krebsimmuntherapie | |
SG11202010528XA (en) | Combinations for treating cancer | |
EP3796891A4 (de) | Therapeutische konstrukte zur behandlung von krebs | |
IL287652A (en) | Cancer treatment | |
EP3990022A4 (de) | Antikörper gegen cd33 zur behandlung von krebs | |
EP3922251A4 (de) | Adjuvans für krebsimmunotherapie | |
IL289006A (en) | Combined immunotherapy for cancer | |
EP3755341A4 (de) | Kombinationstherapien zur behandlung von krebs | |
IL285466A (en) | Cancer treatment | |
EP3962919A4 (de) | Verbindungen zur behandlung von krebs | |
EP4025204A4 (de) | Krebsimmuntherapie | |
EP3969012A4 (de) | Verfahren in bezug auf eine laufende behandlung von krebs | |
EP3894561A4 (de) | Verfahren zur behandlung von krebs | |
GB201909468D0 (en) | Compounds for treating cancer | |
IL288035A (en) | Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210927 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NYKODE THERAPEUTICS ASA Owner name: NEKTAR THERAPEUTICS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230306 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20230228BHEP Ipc: C12N 7/00 20060101ALI20230228BHEP Ipc: C07K 16/28 20060101ALI20230228BHEP Ipc: A61K 39/00 20060101AFI20230228BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231003 |